News from blueprint medicines corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 23, 2022, 16:26 ET Blueprint Medicines Appoints Habib Dable to its Board of Directors

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr. Dable, who was Chief...

Jun 09, 2022, 07:00 ET Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis

-- New analyses showing AYVAKIT® (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world data...

Jun 03, 2022, 16:01 ET Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

May 05, 2022, 16:01 ET Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

May 03, 2022, 07:00 ET Blueprint Medicines Reports First Quarter 2022 Results

-- Achieved $23.8 million in AYVAKIT® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in...

Apr 26, 2022, 08:00 ET Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May...

Apr 08, 2022, 13:00 ET Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer

-- Early dose escalation data show dose-dependent reductions in ctDNA and tumor burden -- -- Generally well-tolerated with most AEs Grade 1 or 2,...

Apr 06, 2022, 16:00 ET Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Mar 25, 2022, 10:15 ET Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Commission (EC) has expanded the current indication for AYVAKYT®...

Mar 08, 2022, 16:30 ET Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new clinical and preclinical data for multiple programs across its...

Mar 04, 2022, 16:01 ET Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Feb 28, 2022, 08:00 ET Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics today announced a strategic collaboration to advance novel targeted...

Feb 16, 2022, 07:00 ET Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year...

Feb 11, 2022, 16:00 ET Blueprint Medicines to Present at Upcoming Investor Conferences

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences. SVB Leerink 11th...

Feb 09, 2022, 08:00 ET Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday,...

Feb 04, 2022, 16:01 ET Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Jan 28, 2022, 08:00 ET Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...

Jan 20, 2022, 08:00 ET Blueprint Medicines Elevates Two Talented Leaders to its Executive Team

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced two executive leadership changes highlighting the company's commitment to developing...

Jan 10, 2022, 08:00 ET Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership

Blueprint Medicines Corporation (NASDAQ: BPMC) today outlined upcoming portfolio milestones that are anticipated to extend its position as a leading...

Jan 06, 2022, 16:01 ET Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Jan 05, 2022, 08:00 ET Blueprint Medicines Announces CEO and Leadership Transition Plan

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that its Board of Directors has appointed Kate Haviland to succeed Jeff Albers as...

Dec 30, 2021, 08:51 ET Blueprint Medicines Completes Acquisition of Lengo Therapeutics

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of...

Dec 09, 2021, 16:01 ET Blueprint Medicines Appoints Daniella Beckman to its Board of Directors

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Daniella Beckman to its board of directors. Ms. Beckman, who is...

Dec 07, 2021, 16:01 ET Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Dec 06, 2021, 16:01 ET Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced two Nature Medicine publications on the registration-enabling EXPLORER and PATHFINDER...